<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36939">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02064621</url>
  </required_header>
  <id_info>
    <org_study_id>144HPS13013</org_study_id>
    <nct_id>NCT02064621</nct_id>
  </id_info>
  <brief_title>CKD-330 Drug-Drug Interaction Study (Candesartan)</brief_title>
  <acronym>CKD-330(C)</acronym>
  <official_title>A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Candesartan Between Free Combination of Candesartan and Amlodipine and Candesartan Monotherapy in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a pharmacokinetic drug interaction and safety of
      Candesartan between free combination of Candesartan and Amlodipine and Candesartan
      monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUCτ,ss of Candesartan</measure>
    <time_frame>1D 0h, 8D 0h, 9D 0h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 10D 0h, 11D 0h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of Candesartan</measure>
    <time_frame>1D 0h, 8D 0h, 9D 0h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 10D 0h, 11D 0h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of Candesartan</measure>
    <time_frame>1D 0h, 8D 0h, 9D 0h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 10D 0h, 11D 0h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>C(Candesartan 32mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan 32mg 1T, PO, QD for 9days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B(Candesartan 32mg/Amlodipine 10mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan 32mg</intervention_name>
    <description>Candesartan 32mg 1T, PO, QD for 9days</description>
    <arm_group_label>B(Candesartan 32mg/Amlodipine 10mg)</arm_group_label>
    <other_name>Atacand Tab. 32mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan 32mg/Amlodipine 10mg</intervention_name>
    <description>Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days</description>
    <arm_group_label>C(Candesartan 32mg)</arm_group_label>
    <other_name>Atacand Tab. 32mg/Norvasc Tab. 10mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteer is between 20 and 45 years of age(inclusive) at the
             pre-study(screening).

          2. Volunteer who has 19kg/m² ≤ BMI(Body Mass Index) ≤ 26kg/m²

          3. When volunteer in screening, Must include under the items.

               1. 100 mmHg ≤ sitting SBP &lt;140 mmHg

               2. 60 mmHg ≤ sitting DBP &lt; 90 mmHg

               3. 45 bpm ≤ Pulse &lt; 95 bpm

          4. Those who decided to join the clinical trials by themselves and to comply with the
             precautions written consent.

        Exclusion Criteria:

          1. A previous history or present of clinically significant liver, renal,
             gastro-intestinal, pulmonary, musculoskeletal, endocrine, neuropsychiatric,
             hemato-oncological, cardiovascular disease.

          2. Have a gastrointestinal disease history that can affect drug absorption(Crohn's
             disease, Ulcers, GERD, Gastritis, etc.) or surgery (except simple appendectomy or
             hernia surgery).

          3. The history of clinically significant hypersensitivity reaction about Investigational
             drugs and foods.

          4. The history of drug abuse or drug abuse showed a positive for urine drug test.

          5. Taking drugs have received any other investigational drug within 90 days prior to the
             first dosing and metabolizing enzyme inducers or inhibitors such as barbitals within
             30 days prior to the first dosing.

          6. Whole blood donation within 60 days prior to the first dosing or plasma donation
             within 30 days prior to the first dosing.

          7. Taking drugs that clinical trials expected to affect within 14days or taking food
             containing caffeine, grapefruit within 7days before the first dosing.

          8. A heavy alcohol consumer(alcohol&gt;3cup/day or 3times/week within last 1month)

          9. A heavy smoker(cigarette&gt;10cigarettes/day)

         10. The subject has positive results of serum tests(Hepatitis B, C, HIV Test, Syphilis).

         11. Have the Liver enzyme levels(AST, ALT) or Bilirubin, total results greater than 1.5
             times the UNL.

         12. Have the result of Creatinine clearance is less than 80mL/min(Cockcroft-Gault
             equation applicable).

         13. The result of 12-lead ECG in screening test is QTc&gt;450msec.

         14. An impossible one who participants in clinical trial by investigator's decision
             including laboratory test result or another reason.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun-Seop Bae, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyun-Seop Bae, Professor</last_name>
    <phone>82-2-3010-4611</phone>
    <email>ksbae@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yo-Han Kim, M.D.</last_name>
    <phone>82-2-3010-4615</phone>
    <email>bestdoctor@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyun-Seop Bae, Professor</last_name>
      <phone>82-2-3010-4611</phone>
      <email>ksbae@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Yo-Han Kim, M.D.</last_name>
      <phone>82-2-3010-4615</phone>
      <email>bestdoctor@amc.seoul.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Kyun-Seop Bae, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 14, 2014</lastchanged_date>
  <firstreceived_date>February 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
